LEAN PCOS AS A DISTINCT PHENOTYPE: METABOLIC DYSFUNCTION, DIAGNOSTIC IMPLICATIONS, AND THE EMERGING ROLE OF GLP-1–BASED THERAPIES
Authors:
- Kaja StolarskaKSKaja Stolarska
- Antonina Gaj-HunterAGAntonina Gaj-Hunter
- Patrycja RęDziniakPRPatrycja RęDziniak
- Alicja RuzikARAlicja Ruzik
- Monika RajsMRMonika Rajs
- Patrycja PrzebieradłoPPPatrycja Przebieradło
- Sandra ŻakSŻSandra Żak
- Monika KowalskaMKMonika Kowalska
- Katarzyna ŻurekKŻKatarzyna Żurek
- Sandra TerpiłowskaSTSandra Terpiłowska
Open Access
- 26 June 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Abstract
Background: Polycystic Ovary Syndrome (PCOS) affects 5–26% of reproductive-age women, yet current diagnostic frameworks insufficiently distinguish metabolically distinct phenotypes, particularly lean PCOS (BMI ≤25 kg/m²). Objective: This narrative review evaluates lean PCOS as a distinct pathophysiological entity and discusses its neuroendocrine and metabolic features, diagnostic challenges, and weight-stratified classification approaches. Methods: A literature search of PubMed, Google Scholar, and clinical guidelines (2015–2026) was conducted, including meta-analyses and comparative studies of lean and obese PCOS phenotypes. Results: Lean PCOS is characterized by neuroendocrine predominance (elevated LH/FSH ratio, adrenal androgen excess), intrinsic insulin resistance independent of BMI, and altered adipokine signaling reflecting adipose tissue dysfunction. Despite relatively favorable cardiometabolic profiles, patients exhibit subclinical hepatic and vascular risk. Genetic studies confirm distinct metabolic and insulin-signaling pathway involvement. Conclusions: Lean PCOS represents a biologically distinct phenotype requiring weight-stratified diagnostic strategies and phenotype-specific therapeutic approaches, including investigation of incretin-based therapies.Keywords
This publication has 33 references indexed in Scilit:
- Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus processThe Lancet, 2026
- Polycystic ovary syndrome perspectives from patients and health professionals on clinical features, current name, and renaming: a longitudinal international online surveyeClinicalMedicine, 2025
- Diagnosis Experiences in Individuals With Lean Polycystic Ovary SyndromeNursing for Women's Health, 2024
- Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysisScientific Reports, 2024
- ART outcomes in lean compared to obese phenotypes of polycystic ovarian syndromeJournal of Assisted Reproduction and Genetics, 2023
- Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?Journal of Endocrinological Investigation, 2023
- The Associations Between Alanine Aminotransferase and Other Biochemical Parameters in Lean PCOSReproductive Sciences, 2022
- PCOS and nutritional approaches: Differences between lean and obese phenotypeMetabolism Open, 2021
- Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategiesMolecular Metabolism, 2020
- Lean polycystic ovary syndrome (PCOS): an evidence-based practical approachJournal of Diabetes & Metabolic Disorders, 2018